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Abstract
Introduction: We recently reported macrophage accumulation in adipose tissue of critically ill patients. Classically
activated macrophage accumulation in adipose tissue is a known feature of obesity, where it is linked with
increasing insulin resistance. However, the characteristics of adipose tissue macrophage accumulation in critical
illness remain unknown.
Methods: We studied macrophage markers with immunostaining and gene expression in visceral and
subcutaneous adipose tissue from healthy control subjects (n = 20) and non-surviving prolonged critically ill
patients (n = 61). For comparison, also subcutaneous in vivo adipose tissue biopsies were studied from 15
prolonged critically ill patients.
Results: Subcutaneous and visceral adipose tissue biopsies from non-surviving prolonged critically ill patients
displayed a large increase in macrophage staining. This staining corresponded with elevated gene expression of
“alternatively activated” M2 macrophage markers arginase-1, IL-10 and CD163 and low levels of the “classically
activated” M1 macrophage markers tumor necrosis factor (TNF)-a and inducible nitric-oxide synthase (iNOS).
Immunostaining for CD163 confirmed positive M2 macrophage staining in both visceral and subcutaneous adipose
tissue biopsies from critically ill patients. Surprisingly, circulating levels and tissue gene expression of the alternative
M2 activators IL-4 and IL-13 were low and not different from controls. In contrast, adipose tissue protein levels of
peroxisome proliferator-activated receptor-g (PPARg), a nuclear receptor required for M2 differentiation and acting
downstream of IL-4, was markedly elevated in illness. In subcutaneous abdominal adipose tissue biopsies from
surviving critically ill patients, we could confirm positive macrophage staining with CD68 and CD163. We also
could confirm elevated arginase-1 gene expression and elevated PPARg protein levels.
Conclusions: Unlike obesity, critical illness evokes adipose tissue accumulation of alternatively activated M2
macrophages, which have local anti-inflammatory and insulin sensitizing features. This M2 macrophage
accumulation may contribute to the previously observed protective metabolic activity of adipose tissue during
critical illness.
Introduction
In our previous study on the role of adipose tissue dur-
ing critical illness, we reported a remarkable accumula-
tion of macrophages in adipose tissue of prolonged
critical ill patients and prolonged critically ill rabbits [1].
Such sudden accumulation of adipose tissue macro-
phages is a known feature of obesity, where it is linked
with increased insulin resistance [2,3]. Recent findings
demonstrate that adipose tissue of healthy, lean indivi-
duals contains a resident population of “alternatively
activated” or M2 macrophages, whereas obesity related
adipose tissue expansion appears to induce an infiltra-
tion of “classically activated” or M1 macrophages [4,5].
These M1 macrophages produce pro-inflammatory cyto-
kines, such as tumor necrosis factor alpha (TNF-a),
thereby contributing to a local and systemic chronic
inflammatory status and insulin resistance [2-5]. In obe-
sity, the increase in adipocyte cell size is suggested to be
the trigger for this macrophage accumulation, as there is
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and the amount of macrophages [2,3].
Why critical illness appears to be associated with
increased infiltration of macrophages in adipose tissue is
not clear. In contrast with obesity, critical illness
induced a decrease in adipocyte cell size [1]. Further-
more, whether critical illness induces an increase in M1
or M2 macrophages in adipose tissue remains to be
identified. M1 macrophages are mainly activated by
interferon-gamma (IFN-g). They have an enhanced pro-
inflammatory cytokine production (TNF-a,I L - 6 ,I L - 1 2 )
and generate excessive nitric oxide levels through indu-
cible nitric-oxide synthase (iNOS) activation. In contrast,
macrophages are polarized to the M2 state by IL-4 and
IL-13. M2 macrophages secrete high levels of the anti-
inflammatory cytokine IL-10 and produce arginase-1,
which metabolizes arginine to ornithine. By directly
competing for the substrate arginine, activation of argi-
nase-1 will also antagonize iNOS action [6,7].
We previously reported that adipose tissue from criti-
cally ill patients displayed a larger number of small adi-
pocytes in response to critical illness, with an increased
ability to take up circulating glucose and triglycerides
[1]. These changes rather point to increased insulin sen-
sitivity in the adipose tissue and would contradict with a
local increase of pro-inflammatory, TNF-a producing
M1 macrophages. Therefore, we hypothesized that criti-
cal illness induces an accumulation of anti-inflamma-
tory, insulin sensitizing M2 macrophages. To determine
the characteristics of the macrophage accumulation in
adipose tissue of the critically ill, we studied abdominal
subcutaneous and visceral adipose tissue biopsies and
s e r u mo f6 1n o n - s u r v i v i n gp r olonged (more than three
days) critically ill patients and 20 demographically
matched controls. Finally, we confirmed our findings in
15 in vivo sampled abdominal adipose tissue needle
biopsies from prolonged critically ill patients.
Materials and methods
Patients
Postmortem biopsy samples of abdominal subcutaneous
and omental adipose tissue were harvested within min-
utes after death from 61 long-stay critically ill patients
with an intensive care unit (ICU) stay of at least three
days. Patients were all enrolled in a large prospective,
randomized controlled study on the effects of intensive
insulin therapy on outcome of critical illness [8]. The
detailed protocol of the study has been previously pub-
lished [8]. We collected biopsies from 33 conventionally
treated patients and 28 samples from intensive insulin
treated patients. For postmortem tissue sampling for
academic purposes, each patient or his/her legal repre-
sentative consented upon admission, via a hospital-wide
information and consent procedure, which requires
active opting-out when not consenting. Opting-out
remained possible until time of death. This strategy was
approved by the Institutional Ethical Review Board
(ML1820). The baseline and outcome characteristics of
the critically ill patients from whom postmortem adi-
pose tissue biopsies were collected, are described in
Table 1. For comparison, we also collected abdominal
subcutaneous and omental adipose tissue biopsy samples
from demographically matched patients, who were not
critically ill, and who underwent elective abdominal sur-
gery for restorative rectal resection (ML 2707). These
patients provided written informed consent prior to the
procedure. From 15 long-stay patients, we collected in
vivo abdominal subcutaneous adipose tissue needle
biopsies on Day 7 of their ICU stay. The in vivo biopsies
were taken after a specific written informed consent
from the patient or his/her legal representative (ML
4190). The baseline characteristics of the critically ill
patients from whom in vivo adipose tissue biopsies were
collected are described in Table 2. The protocols and all
consent forms were approved by the Institutional Ethical
Review Board (ML 1820 and ML 2707, ML 4190). All
tissue samples were snap-frozen in liquid nitrogen and
stored at -80°C until analysis.
Adipocyte morphology
Tissue samples were fixed in 6% paraformaldehyde over-
night. Paraffin wax sections of 6 μm were processed for
immunostaining. Sections were stained with a primary
anti-macrophage CD68 antibody (Dako, Glostrup, Den-
mark) and CD163 antibody (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) and counterstained with hema-
toxylin. Staining was evaluated at a 10 × and 40 × mag-
nification using a Leica DM3000 Microscope (Leica,
Wetzlar, Germany).
Gene expression
Tissue samples were homogenized with a Precellys 24
machine using CK14 tubes (Bertin Technologies, Vil-
leurbanne, France) containing ceramic beads at 6,500
rpm for one cycle of 45 sec in Qiazol (Qiagen, Hilden,
Germany). RNA was isolated using the RNeasy mini
RNA isolation kit (Qiagen) and quantified by Nanodrop
spectrophotometer (ND-1000, Nanodrop Technologies,
Wilmington, DE, USA). Samples were treated with
DNAse to remove all contaminating genomic DNA. A
t o t a lo f5 0 0t o2 5 0n go ft o t a lR N Aw a sr e v e r s e - t r a n -
scribed using Superscript III Reverse Transcriptase
(Invitrogen, Merelbeke, Belgium) and random primers
(Invitrogen). In a first run, all postmortem samples and
healthy controls were reverse transcribed simulta-
neously. In a second run, all in vivo samples and healthy
controls were reverse transcribed simultaneously. One-
fifth of dilutions of reverse transcribed RNA samples
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(Applied Biosystems, Carlsbad, CA, USA), which uses
TaqMan chemistry for highly accurate quantization of
mRNA levels. Unknown samples were run in duplicate
and individual samples with a Cycle threshold (Ct) value
standard deviation greater than 0.3 were reanalyzed.
Data were analyzed using the comparative Ct method.
Data are expressed normalized to glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) expression and as a
fold change of the mean of the controls. GAPDH, argi-
nase-1, IL-10, iNOS, CD163, IL-4, IL-13 and TNF-a
gene expression assays from Applied Biosystems were
used.
Serum analyses
Serum levels of IFN-g, IL-4, IL-10 and IL-13 were mea-
sured with high sensitivity ELISAs (eBioscience, San
Diego, CA, USA) according to the manufacturer’s
protocol.
Immunoblot analysis
Tissue samples were weighed and homogenized with a
Precellys 24 machine using CK14 tubes containing cera-
mic beads at 6,000 rpm for one cycle of 30 sec in lysis
buffer containing phosphatase inhibitors. The homoge-
nates were centrifuged for 10 minutes at 5,000 rpm and
4°C. The protein content in the homogenate was deter-
mined with a Coomassie Protein Assay Reagent
(Thermo Scientific Pierce, Rockford, IL, USA). An equal
amount of protein was loaded for each sample and
homogenates were separated by denaturating SDS-
PAGE and immunoblotted with a specific Ab against
peroxisome proliferator-activated receptor-g (PPARg)






Gender (no. male) 14 36
Age (yr) (mean ± SD) 70 ± 12 67 ± 15
BMI (kg/m
2) (mean ± SD) 25.0 ± 2.6 24.1 ± 3.5
History of diabetes (no.) 3 9
APACHE-II score on admission (median (IQR)) - 26 (20 to 34)
Admission diagnose -
- Cardiovascular 5
- Gastrointestinal or liver 5





ICU stay (median (IQR)) 0 10 (6 to 19)
Cause of death in ICU -
- Severe brain damage 2
- Respiratory failure 26
- Therapy resistant septic shock/cardiovascular collapse 14
- Persistent MOF after septic or SIRS induced shock 19
APACHE II, Acute Physiology and Chronic Health Evaluation II; BMI, body mass index; ICU, intensive care unit; IQR, interquartile range; MOF, multiple organ failure;
SD, standard deviation; SIRS, systemic inflammatory response syndrome; Yrs, years.
Table 2 Characteristics of surviving critically ill patients
Number 15
Gender (no. male) 11
Age (yr) (mean ± SD) 56 ± 16
BMI (kg/m
2) (mean ± SD) 28.1 ± 5.2
APACHE-II score on admission (median (IQR)) 30 (23 to 40)
Admission diagnose
- Cardiac surgery 1
- Transplantation 1
- Trauma, burns or reconstructive surgery 5
- Complicated thoracic surgery 2
- Complicated vascular surgery 1
- Gastroenterologic or hepatic disease 1
- Complicated neurosurgery 2
- Hematological or oncological disease 1
- Renal disease 1
ICU stay (median (IQR)) 22 (13 to 28)
Deaths during intensive care - no. (%) 1 (7%)
The in vivo abdominal subcutaneous adipose tissue biopsies were sampled at
Day 7 of the patients ICU stay. APACHE II, Acute Physiology and Chronic
Health Evaluation II; BMI, body mass index; ICU, intensive care unit; IQR,
interquartile range; MOF, multiple organ failure; SD, standard deviation; SIRS,
systemic inflammatory response syndrome; Yrs, years.
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HRP-conjugated secondary Ab. All blots were analyzed
using Image Master Software (GE Healthcare Europe,
Chalfont St. Giles, UK).
Statistics
We used ANOVA and unpaired t-test for normally dis-
tributed data and the non-parametric Kruskal-Wallis
and Mann-Whitney U test when data appeared to be
not normally distributed. Statistical significance was
considered when P-values were ≤ 0.05.
Results
Characterization of the macrophages
We described earlier that subcutaneous and visceral adi-
pose tissue biopsies from critically ill patients display a
large number of CD68 positive cells, which is a general
macrophage marker. This was in sharp contrast with
biopsies from healthy controls where only occasionally
some CD68 positive cells were observed [1]. Positive
cells displayed macrophage morphology and were found
scattered throughout the adipose tissue (Figure 1).
Depending on the activation, macrophages can polar-
ize to a M1- or M2- phenotype. Each phenotype
expresses specific markers, allowing the identification of
the phenotype. TNF-a and iNOS are specific markers
for the M1 phenotype. In a selection of 61 human post-
mortem adipose tissue biopsies, TNF-a gene expression
was decreased in both the subcutaneous and visceral
depot, compared to healthy controls (Figure 2A). We
could also demonstrate a decreased iNOS gene expres-
sion in visceral adipose tissue (from 0.81 (0.54 to 1.3) in
healthy individuals to 0.34 (0.23 to 0.81) median (IQR)
in non-surviving critically ill patients, P = 0.0095), with
unaltered levels in the subcutaneous adipose tissue of
nonsurviving critically ill patients (from 0.91 (0.70 to
1.22) in health, to 0.82 (0.31 to 2.05) in critical illness, P
= 0.9). These observations suggest that the macrophages
we identified in adipose tissue of critically ill patients
are not of the pro-inflammatory M1-type.
Therefore, we tested adipose tissue expression level of
the specific M2 marker arginase-1 in the same selection
of 61 nonsurviving critically ill patients. In contrast with
the M1 markers, arginase-1 gene expression was
increased several-fold in both visceral and subcutaneous
depots (Figure 2B). Two other markers for M2 pheno-
type macrophages, CD163 and IL-10, were comparably
elevated in the human postmortem visceral and subcuta-
neous adipose tissue biopsies (Figure 2C, D). Because
gene expression levels were measured in total adipose
tissue, we confirmed the cell specificity of the M2-mar-
kers with immunostaining in a random selection of the
available postmortem biopsies. In the nonsurviving criti-
cally ill patients, 9 out of 10 omental adipose tissue
biopsies and 10 out of 10 subcutaneous adipose tissue
biopsies stained positive for CD163 whereas in healthy
controls none of the tested omental (n = 10) nor subcu-
taneous (n = 10) biopsies stained positive for CD163.
Positive CD163 staining pattern in the biopsies from cri-
tically ill patients was comparable to the CD68 staining
pattern (Figure 2E).
Functionally, M2 macrophages will produce high levels
of IL-10, whereas iNOS expression and concomitant
NO-production might be reduced. Indeed, in serum
Figure 1 Macrophage staining with CD68 in abdominal subcutaneous adipose tissue. Biopsies from two non-critically ill volunteers (a, b)
and four critically ill, non-surviving patients (c-f).
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clearly elevated in the patients compared to healthy con-
trols (Figure 2F). However, the levels did not correlate
significantly with tissue gene expression level, pointing
to other IL-10 sources besides adipose tissue residing
macrophages.
Possible triggers for macrophage accumulation
The primary trigger for M1 type activation is IFN-g.I n
serum samples collected on the day of the biopsy, IFN-g
levels were low (mean ± SE 1.77 ± 0.49 pg/ml) in criti-
cally ill patients, but not different from healthy control
samples (P = 0.9). The most common activators of M2
macrophages are the anti-inflammatory cytokines IL-4
and IL-13. IL-4 serum levels were however below detec-
tion limit (90% of the patients) or very low. IL-13 levels
were low (6.24 ± 2.70 pg/ml), and not different from
healthy control samples (P = 0.9). Adipocytes and resid-
ing macrophages can also locally produce cytokines,
which might trigger M2 type activation. Gene expression
of IL-4 and of IL-13 was low to undetectable in both
visceral and omental adipose tissue postmortem biopsies
and no difference could be detected from healthy
volunteers.
More downstream of cytokine activation, PPARg,
which is a nuclear receptor expressed in high levels in
a d i p o s et i s s u e ,i sap o s s i b l et rigger for M2 polarization.
It plays a pivotal part in adipogenesis, lipid biosynthesis,
insulin sensitivity, but has also been demonstrated to
stimulate the formation of M2 macrophages. IL-4 and
IL-13 are known to activate PPARg. With Western blot-
ting, we could clearly demonstrate increased levels of
PPARg in both subcutaneous and visceral postmortem
adipose tissue biopsies from critically ill patients, com-
pared to healthy controls (Figure 3).
Confirmation in vivo
We were able to collect in vivo small needle biopsies
from abdominal subcutaneous adipose tissue in 15 criti-
cally ill patients at Day 7 of their ICU stay. Of the 15
patients from which we sampled in vivo biopsies, 14
patients survived their ICU and hospital stay. Only one
patient died in the ICU, and this was after 121 days
(114 days after the day of the biopsy).
Paraffin sections of the in vivo biopsies stained posi-
tive for CD68 (Figure 4A) and CD163 (Figure 4B),
confirming our findings of the postmortem biopsies.
We also quantified arginase-1 and TNF-a gene
Figure 2 M1 and M2 macrophage markers in adipose tissue from healthy controls and critically ill, non-surviving patients.A d i p o s e
tissue (A.T.) mRNA levels of (A) TNF-a,( B) Arginase-1, (C) CD163, (D) and IL-10 (D). (E) Adipose tissue biopsy staining for CD163 from one
representative patient, and (F) serum IL-10 levels on the day of sampling. Databoxes present median and interquartile range; whiskers represent
the 10
th and the 90
th percentiles. Grey boxes represent healthy controls undergoing elective surgery (healthy, n = 20); white boxes are critically
ill patients (crit. Ill, n = 61). Different from healthy controls with *P ≤ 0.05, ** P ≤ 0.01. AU, arbitrary units.
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control samples. Confirming our findings in the non-
surviving patients, we could demonstrate in these sur-
viving patients a clearly increased gene expression of
the M2-marker arginase-1 (Figure 4C), whereas TNF-a
was not altered compared to healthy controls (healthy
controls 0.98 (0.75 to 1.37), critically ill patients 0.90
(0.35 to 1.83), P = 0.37). Samples were also used for
protein analysis, with which we could confirm an
increase in PPARg compared to healthy controls (Fig-
ure 4D).
Impact of insulin or steroid treatment
Treatment with insulin or corticosteroids might influ-
ence the inflammatory state of the patient and conse-
quently influence macrophage polarization. The patients
from which we studied postmortem biopsies were all
enrolled in a randomized controlled trial on blood glu-
cose control [8]. From the 61 studied nonsurviving
patients, 33 patients were on conventional insulin regi-
men, which resulted in mean blood glucose levels of
157 ± 4 mg/dl (mean ± SE), 28 patients were on inten-
sive insulin therapy which resulted in mean blood
Figure 3 Adipose tissue levels of protein PPARg from healthy controls and critically ill, non-surviving patients. Databoxes present
median and interquartile range; whiskers represent the 10
th and the 90
th percentiles. Grey boxes represent healthy controls undergoing elective
surgery (healthy, n = 20); white boxes are critically ill patients (crit. Ill, n = 61). Different from healthy controls with ** P ≤ 0.01. AT, adipose tissue;
AU, arbitrary units.
Figure 4 Macrophage markers in adipose tissue from (healthy controls and critically ill, surviving patients. Positive CD68 (A) and CD163
(B) staining in in vivo abdominal subcutaneous biopsies from critically ill patients. (C) Adipose tissue levels of arginase-1 gene expression. (D)
Adipose tissue levels of protein PPARg. Databoxes present median and interquartile range; whiskers represent the 10
th and the 90
th percentiles.
Grey boxes represent healthy controls undergoing elective surgery (healthy, n = 20); white boxes are critically ill patients from which in vivo
biopsies were collected (crit. Ill, n = 15). Different from healthy controls with * P ≤ 0.05. AU, arbitrary units.
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Page 6 of 9glucose levels of 110 ± 3 mg/dl. Both patient groups dis-
played elevated insulin levels on the day of biopsy, 12.1
(7.0 to 31.2) mIU/l (median (IQR)) for the conventional
group, 29.3 (10.2 to 83.2) mIU/l for the intensive insulin
treated group, and only 6.2 (6.0 to 7.4) mIU/l for the
healthy control group. Although the two treatment
groups displayed different glucose levels and different
circulating insulin levels, this did not result in a different
expression level of any of the tested macrophage mar-
kers. Also, the tested circulating cytokines did not differ
between the two treatment groups. Although insulin is
known for its anti-inflammatory actions [9,10], insulin
therapy had apparently no impact on either macrophage
marker expression profile or cytokine levels. This con-
firms earlier findings in which insulin therapy had no
[11] or very minor [12] impact on circulating cytokines,
irrespective of its anti-inflammatory actions [10].
In the postmortem patient population, 51 out of 61
patients (84%) received steroids during their ICU stay.
In the in vivo patient population, 6 out of 15 patients
(40%) received steroids before the biopsy sampling.
Treated and untreated patients displayed similar levels
for the tested macrophage markers and circulating cyto-
kines. Treatment with steroids thus appeared not to
affect macrophage polarization in adipose tissue.
Discussion
In this study, we demonstrated that critical illness
induces an accumulation of alternatively active M2
macrophages in adipose tissue. High levels of PPARg in
the adipose tissue of critically ill patients could explain
this accumulation, rather than high circulating cytokine
levels.
The activation of M1 macrophages is a classical fea-
ture of cellular immunity to infection while the alterna-
tive activation of M2 macrophages is considered to have
a role in humoral immunity and repair. Alternatively
activated M2 macrophages have been implicated in
immunity, inflammation, allergy, parasitic infections,
repair, metabolic functions and malignancy [6]. Alterna-
tively activated macrophages express high levels of the
enzyme arginase-1 [13]. Arginase-1 was classically an
enzyme considered to be exclusively expressed in the
liver, but is now recognized to also occur in cells of the
immune system. Arginase-1 is the enzyme that produces
ornithine, the precursor of polyamines and proline.
Polyamines participate in a variety of cellular processes,
such as cell proliferation and tissue regeneration [14].
Activation of arginase-1 also counteracts iNOS action
by competing for the same substrate arginine, thereby
inhibiting the biosynthesis of nitric oxide [15]. CD163
and IL-10, two other markers of alternative macrophage
activation, were also up-regulated in adipose tissue of
critically ill patients [16,17]. CD163 is the scavenging
receptor for hemoglobin, exclusively expressed by
monocytes and tissue macrophages [17,18]. Macro-
phages are the primary scavengers of hemoglobin after
systemic hemolysis and during wound healing, two pro-
cesses which are often ongoing during critical illness.
IL-10 is a strong anti-inflammatory cytokine that condi-
tions the activation and function of immune cells, selec-
tively blocks the expression of pro-inflammatory genes
and enhances the expression of anti-inflammatory mole-
cules [19]. In critically ill patients, adipose tissue IL-10
expression, as well as IL-10 in circulation, was clearly
elevated. We could not, however, demonstrate a clear
association between circulating IL-10 levels and expres-
sion levels in adipose tissue, which suggests other possi-
ble sources for IL-10. Possibly, the produced IL-10, but
also CD163 and arginase in adipose tissue macrophages
only play a paracrine role, thereby preventing adipose
tissue injury from excess inflammation and insulin resis-
tance. Remarkably, circulating mononuclear cells from
critically ill patients also appear to be switched to the
M2-phenotype [20,21].
Once the polarization state of the macrophages was
determined, we tried to identify the trigger for the M2
polarization in adipose tissue of critical illness. Macro-
phages are polarized to the M1 state through the classical
activation pathway by the TH1c y t o k i n eI F N - g,w h i l et h e
alternative activation with TH2 cytokines IL-4 and IL-13
polarizes macrophages to the M2 phenotype [6,13,22]. In
our experimental setup, IFN-g, IL-4 or IL-13 was not up-
regulated in circulation. Also, locally produced cytokines
might trigger macrophage polarization. We, however, did
not find an up-regulation of IL-4 or IL-13 expression.
Our methodology in which we measured gene expression
in total adipose tissue might possibly not be sensitive
enough to measure a mild up-regulation of IL4 or IL13
only in adipocytes. However, critically ill patients often
suffer from systemic inflammatory response syndrome
(SIRS) or sepsis, associated with high circulating levels of
several pro-inflammatory and anti-inflammatory cyto-
kines. Possibly, it is this cocktail of cytokines, which is
responsible for the pro-inflammatory activation of
macrophages in adipose tissue.
We were able to identify a more downstream activator
of M2 polarization. PPARg is a transcription factor that
has been characterized as a key signal in alternative M2
macrophage activation [13,23]. We clearly found
increased PPARg protein levels in adipose tissue of criti-
cally ill patients, both in postmortem biopsies and in
vivo. Although it has been demonstrated that IL-4 and
IL-13 can activate PPARg, other possible activators for
PPARg are fatty acids and prostaglandines [13,24,25].
Possibly high circulating lipid levels, often observed in
critically ill patients, play a role in the observed PPARg
activation [26-28].
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highlighted. Because the available biopsies were all snap-
frozen at the time of biopsy, we were not able to isolate
adipocytes from the stromal cell fraction. Gene and pro-
tein expression were, therefore, quantified in whole adi-
pose tissue homogenates.
Conclusions
In conclusion, we demonstrated that unlike obesity, cri-
tical illness evokes accumulation of alternatively acti-
vated M2 macrophages in adipose tissue. M2
accumulation in the adipose tissue could be considered
as a beneficial response promoting anti-inflammatory
actions, wound healing and scavenging of hemoglobin.
Whether or not the M2 macrophages only play a local
role in the adipose tissue, or are a source of polyamines
and soluble CD163 in the circulation cannot be con-
cluded from this study. Possibly also other tissues, such
as the liver, might display increased macrophage infiltra-
tion and M2 polarization during critical illness, for
which further study is needed.
Key messages
￿ Irrespective of the admission diagnosis, prolonged
critically ill patients display accumulation of macro-
phages in adipose tissue.
￿ These tissue macrophages display characteristics of
alternatively activated M2 macrophages.
￿ The key trigger for this accumulation might be an
increase in PPARg activity.
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